PROF Pengajuan SEC - Profound Medical Corp.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1628808

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Profound Medical Corp.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 14, 2025	EX-99.1	Profound Medical Announces Second Quarter 2025 Financial Results EXHIBIT 99.1 Profound Medical Announces Second Quarter 2025 Financial Results TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for t
August 14, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39032 PROFOUND MEDICAL CORP.
August 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 PROFOUND MEDICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (
June 4, 2025	EX-99.1	Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO® EXHIBIT 99.1 Famed Former NFL Safety, Leonard Wheeler, Named Global Ambassador For TULSA-PRO® TORONTO, June 04, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, is pleased to announce that it h
June 4, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Com
May 14, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Com
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Comm
May 8, 2025	EX-99.1	Profound Medical Announces First Quarter 2025 Financial Results EXHIBIT 99.1 Profound Medical Announces First Quarter 2025 Financial Results TORONTO, May 08, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, AI-powered, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results for the
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39032 PROFOUND MEDICAL CORP.
April 29, 2025	EX-99.1	Establishing TULSA - PRO as the Mainstream Treatment Option for Personalized Prostate Ablation, Malignant or Benign, Without Compromise Prostate Cancer • CAPTAIN Level 1 randomized controlled trial, peri - operative data and patient experience • Dr. Exhibit 99.1 Establishing TULSA - PRO as the Mainstream Treatment Option for Personalized Prostate Ablation, Malignant or Benign, Without Compromise Prostate Cancer • CAPTAIN Level 1 randomized controlled trial, peri - operative data and patient experience • Dr. Ram Pathak’s TULSA experience, outcomes and efficient interventional MRI workflow BPH • Strategy for market introduction of TULSA for BPH
April 29, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C
April 29, 2025	EX-99.1	Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy – First Level 1 study comparing an emerging technology EXHIBIT 99.1 Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy – First Level 1 study comparing an emerging technology head-to-head with RP in men with prostate cancer – – TULSA had no blood loss and no overnight stay, along with reduced post-procedure pa
April 29, 2025	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C
April 22, 2025	EX-99.1	PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 14, 2025 MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 4, 2025 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 14, 2025 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 4, 2025 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) i
April 22, 2025	8-K	Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 PROFOUND MEDICAL CORP. (Exact name of Registrant as Specified in Its Charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (C
March 10, 2025	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5
March 10, 2025	EX-99.3	Form 52 – 109F2 – Certification of Interim Filings – CEO Exhibit 99.3 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended June 30, 2024. I, Arun Menawat, Chief Executive Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (tog
March 10, 2025	EX-99.4	Form 52 – 109F2 – Certification of Interim Filings – CFO Exhibit 99.4 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended March 31, 2024. I, Rashed Dewan, Chief Financial Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (to
March 10, 2025	EX-99.2	Management’s Discussion and Analysis Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Notice to Reader Profound Medical Corp. (the “Company”, “Profound” or the “Group”) now prepares its financial statements filed with the Canadian Securities Administrators and with the Securities and Exchange Commission in accordance with generally accepted accounting principles in
March 10, 2025	EX-99.3	Form 52 – 109F2 – Certification of Interim Filings – CEO Exhibit 99.3 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended March 31, 2024. I, Arun Menawat, Chief Executive Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (to
March 10, 2025	EX-99.1	Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 PROFOUND MEDICAL CORP. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) FOR THE QUARTER ENDED MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Notice of No Auditor Review: In accordance with National Instrument 51-102 - Continuous Disclosure Obligations (“NI 51-102”), Profound Medical Corp. (the “Company”) discloses that its external auditors have not reviewed the accompanying una
March 10, 2025	EX-99.1	Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 PROFOUND MEDICAL CORP. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) FOR THE QUARTER ENDED JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Notice of No Auditor Review: In accordance with National Instrument 51-102 - Continuous Disclosure Obligations (“NI 51-102”), Profound Medical Corp. (the “Company”) discloses that its external auditors have not reviewed the accompanying unau
March 10, 2025	EX-99.1	Unaudited Interim Condensed Consolidated Financial Statements Exhibit 99.1 PROFOUND MEDICAL CORP. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) FOR THE QUARTER ENDED SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Notice of No Auditor Review: In accordance with National Instrument 51-102 - Continuous Disclosure Obligations (“NI 51-102”), Profound Medical Corp. (the “Company”) discloses that its external auditors have not reviewed the accompanying
March 10, 2025	EX-99.4	Form 52 – 109F2 – Certification of Interim Filings – CFO Exhibit 99.4 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended June 30, 2024. I, Rashed Dewan, Chief Financial Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (tog
March 10, 2025	EX-99.2	Management’s Discussion and Analysis Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Notice to Reader Profound Medical Corp. (the “Company”, “Profound” or the “Group”) now prepares its financial statements filed with the Canadian Securities Administrators and with the Securities and Exchange Commission in accordance with generally accepted accounting principle
March 10, 2025	EX-99.3	Form 52 – 109F2 – Certification of Interim Filings – CEO Exhibit 99.3 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended September 30, 2024. I, Arun Menawat, Chief Executive Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A
March 10, 2025	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5
March 10, 2025	EX-99.2	Management’s Discussion and Analysis Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Notice to Reader Profound Medical Corp. (the “Company”, “Profound” or the “Group”) now prepares its financial statements filed with the Canadian Securities Administrators and with the Securities and Exchange Commission in accordance with generally accepted accounting principles in
March 10, 2025	EX-99.4	Form 52 – 109F2 – Certification of Interim Filings – CFO Exhibit 99.4 Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Profound Medical Corp. (the “issuer”) has refiled interim financial statements for the three months ended September 30, 2024. I, Rashed Dewan, Chief Financial Officer of the issuer, certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A
March 10, 2025	6-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5
March 7, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39
March 7, 2025	EX-10.1	Employment Agreement, dated January 1, 2020, as amended, by and between the Company and Arun Menawat Exhibit 10.1 EXECUTION COPY EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of the 1st day of January, 2020 (the “Effective Date”). BETWEEN: PROFOUND MEDICAL (US) INC. (the “Company”) AND, for the limited purposes of Sections 1.1, 2.3 and 16.1 hereof: PROFOUND MEDICAL CORP. (the “Parent”) AND: ARUN MENAWAT (the “Employee”) WHEREAS Parent, which owns 100% of the equity of
March 7, 2025	EX-10.4	Amended and Restated Employment Agreement, dated August 20, 2019, as amended, by and between the Company and Mathieu Burtnyk Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) dated as of August 20, 2019 (the“Effective Date”) BETWEEN: PROFOUND MEDICAL CORP. (the “Company”) AND: MATHIEU BURTNYK (the “Employee”) WHEREAS the Company and the Employee entered into a letter agreement as to employment on June 3, 2011 (the “Original Agreement”); and WHEREAS th
March 7, 2025	EX-10.7	Amended and Restated Technology License Agreement, dated May 16, 2011, by and between the Company and Sunnybrook Health Sciences Centre Exhibit 10.7 AMENDED AND RESTATED TECHNOLOGY LICENCE AGREEMENT THIS AMENDED AND RESTATED TECHNOLOGY LICENCE AGREEMENT is made as of May 16, 2011 BETWEEN: SUNNYBROOK HEALTH SCIENCES CENTRE, with offices located at 2075 Bayview Avenue in Toronto, Ontario (the “Licensor”) - and- PROFOUND MEDICAL INC., a company governed by the laws of the Province of Ontario (the “Licensee”) RECITALS: A. The Inventor
March 7, 2025	EX-10.3	Amended and Restated Employment Agreement, dated August 23, 2019, as amended, by and between the Company and Rashed Dewan Exhibit 10.3 EMPLOYMENT AGREEMENT THIS AGREEMENT dated as of March 22, 2022, has an effective date of February 1, 2022 (the “Start date”), and signed acceptance of this agreement date of on or before March 23, 2022, the expiry date of this offer of employment. BETWEEN: Profound (the “Employer” or “Company”) AND: Rashed Dewan (the “Employee”) WHEREAS: A. The Employer has offered to employ the Emplo
March 7, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (Co
March 7, 2025	EX-10.8	Siemens Agreement dated January 23, 2019. between the Company and Siemens Healthcare GmbH Exhibit 10.8 SIEMENS ID Agreement by and between Profound Medical Inc. (- hereinafter referred to as “the Receiver” -) and SIEMENS Healthcare GmbH (- hereinafter referred to as “SIEMENS” -) - the Receiver and SIEMENS hereinafter referred to individually as “PARTY” or collectively as “PARTIES” - on the provision of information regarding SIEMENS’ interface CONFIDENTIAL 2 / 26 Contents Preamble 3 Art
March 7, 2025	EX-4.2	Specimen Share Certificate Exhibit 4.2
March 7, 2025	EX-10.9	Amended and Restated Credit Agreement, dated March 3, 2025, between the Company and Canadian Imperial Bank of Commerce Exhibit 10.9 [***] Certain information has been excluded from this exhibit because it is both not material and the type that the Registrant treats as private or confidential. AMENDED AND RESTATED CREDIT AGREEMENT between PROFOUND MEDICAL INC. as Borrower AND PROFOUND MEDICAL CORP. 2753079 ONTARIO INC. PROFOUND MEDICAL (U.S.) INC. and PROFOUND MEDICAL GMBH as Guarantors AND CANADIAN IMPERIAL BANK O
March 7, 2025	EX-21	Subsidiaries of the Company Exhibit 21 SUBSIDIARIES OF THE COMPANY Name Subsidiary Jurisdiction Profound Medical Inc. Canada 2753079 Ontario Inc. Canada Profound Medical Oy Finland Profound Medical Technology Services (Beijing) Co., Ltd. China Profound Medical GmbH Germany Profound Medical (U.S.) Inc. United States
March 7, 2025	EX-19	Profound Medical Corp. Corporate Disclosure, Confidentiality and Trading in Securities by Directors, Officers, Employees and Consultants Policy Exhibit 19 Title: CORPORATE DISCLOSURE, CONFIDENTIALITY AND TRADING IN SECURITIES POLICY PAGE 1 of 18 Document Number HR-SP-POLICY019 Revision 3 PROFOUND MEDICAL CORP.
March 7, 2025	EX-10.2	Employment Agreement, dated October 14, 2024, by and between the Company and Tom Tamberrino Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) dated as of the 14th day of October 2024 (the “Effective Date”). BETWEEN: PROFOUND MEDICAL (US) INC. (the “Company”) AND: THOMAS TAMBERRINO (the “Employee”) NOW THEREFORE in consideration of the covenants and agreements herein, the sufficiency of which is acknowledged by each of the parties, the parties agree as follows:
March 7, 2025	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of filing of our Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report on Form 10-K”), Profound Medical Corp. (“Profound,” the “Company,” “we,” “us” and “our”) has one class of securities registered under Section 12 of the Securities Exchange A
March 7, 2025	EX-99.1	Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results TORONTO, March 06, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported unaudited financial results fo
January 8, 2025	8-K	Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 PROFOUND MEDICAL CORP. (Exact name of registrant as specified in its charter) Ontario, Canada 001-39032 Not Applicable (State or Other Jurisdiction of Incorporation) (
January 8, 2025	EX-99.1	Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues – Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC o EXHIBIT 99.1 Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues – Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound reminds investors that it is scheduled to present at JPM 2025 on January 16th at 11:15 a.m. PT – TORON
January 6, 2025	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
January 6, 2025	EX-99.1	Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference EXHIBIT 99.1 Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present
December 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 16, 2024	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Profound Medical Corp. (“Profound” or the “Company”) Unit 6, 2400 Skymark Avenue Mississauga, Ontario L4W 5K5 2. Date of Material Change December 6, 2024 3. News Release A press release relating to the material change was disseminated via Globe Newswire on December 6, 2024 and was subsequently filed on SEDAR+. 4. Summ
December 11, 2024	EX-99.1	Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares EXHIBIT 99.1 Profound Medical Announces Closing of US$40.25 Million Underwritten Public Offering of Common Shares TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of common shares (the “Common Shares”) at a public offering pric
December 11, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 6, 2024	EX-99.1	Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR EXHIBIT 99.1 Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of a
December 6, 2024	EX-99.1	PROFOUND MEDICAL CORP. 4,666,700 Common Shares UNDERWRITING AGREEMENT Exhibit 99.1 Execution Version PROFOUND MEDICAL CORP. 4,666,700 Common Shares UNDERWRITING AGREEMENT December 6, 2024 RAYMOND JAMES LTD. Lake Street Capital Markets, LLC As representatives of the several underwriters c/o Raymond James Ltd. 40 King St. W., 54th Floor Toronto, Ontario M5H 3Y2 c/o Lake Street Capital Markets, LLC 920 Second Avenue South, Suite 700, Minneapolis, MN 55402 United States
December 6, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 6, 2024	EX-99.2	Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR Exhibit 99.2 Profound Medical Announces Pricing of US$35 Million Underwritten Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, ON (December 6, 2024) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced the pricing of an underwr
December 6, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 6, 2024	SUPPL	PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 10, 2024 TABLE OF CONTENTS Filed pursuant to General Instruction II.L of Form F-10 File No. 333-280236 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated July 10, 2024 to which it relates, as amended or supplemented, and each document incorporated
December 5, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 5, 2024	EX-99.1	Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR EXHIBIT 99.1 Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 05, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (th
December 5, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 5, 2024	SUPPL	PRELIMINARY PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 10, 2024 TABLE OF CONTENTS Filed pursuant to General Instruction II.L of Form F-10 File No. 333-280236 A copy of this preliminary prospectus supplement has been filed with the securities regulatory authorities in each of the provinces and territories of Canada but has not yet become final for the purpose of the sale of securities. Information contained in this preliminary prospectus supplement may not b
December 5, 2024	EX-99.1	BOSTON LOS ANGELES NEW YORK SAN DIEGO SAN FRANCISCO TORONTO WASHINGTON MINTZ LLP Exhibit 99.1 200 Bay Street, South Tower Suite 2800 Toronto, ON 647 499 2828 mintz.com December 5, 2024 Profound Medical Corp. 2400 Skymark Avenue, Unit 6 Mississauga, Ontario L4W 5K5, Canada Ladies and Gentlemen: Re: Registration Statement on Form F-10 We hereby consent to the references to our firm name in the prospectus filed as part of this registration statement on Form F-10 of Profound Medic
December 5, 2024	EX-99.2	Osler, Hoskin & Harcourt Exhibit 99.2 Osler, Hoskin & Harcourt llp Box 50, 1 First Canadian Place Toronto, Ontario, Canada M5X 1B8 416.362.2111 main 416.862.6666 facsimile Toronto Montréal Ottawa Calgary New York December 5, 2024 Profound Medical Corp. 2400 Skymark Avenue, Unit #6 Mississauga, Ontario L4W 5K5 Dear Sirs/Mesdames: Profound Medical Corp. (the “Issuer”) We refer you to the prospectus supplement dated December
December 5, 2024	EX-99.3	Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ Exhibit 99.3 Profound Medical Announces Proposed Public Offering of Common Shares BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ TORONTO, ON (December 5, 2024) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) today announced that it intends to offer and sell common shares (the “Common Shares”) in
December 2, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 2, 2024	EX-99.1	Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy – Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurat EXHIBIT 99.1 Profound Medical and Siemens Healthineers to Offer a Complete Solution for MRI-guided Prostate Therapy – Combines Profound’s TULSA-PRO® and Siemens Healthineers’ Magnetom Free.Max – – Supports the Modern Treatment Pathway that allows for more accurate and precise diagnosis, treatment, and follow-up – – Aligns well with CMS 2025 Final Rule establishing Urology APC Level 7 reimbursement
November 26, 2024	EX-99.1	Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’ TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meeti EXHIBIT 99.1 Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’ TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-s
November 26, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 14, 2024	SC 13G/A	PROF / Profound Medical Corp. / GAGNON SECURITIES LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Profound Medical Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 74319B502 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
November 12, 2024	EX-99.1	Profound Medical to Participate in the Stifel 2024 Healthcare Conference EXHIBIT 99.1 Profound Medical to Participate in the Stifel 2024 Healthcare Conference TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an upda
November 12, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 7, 2024	EX-99.3	PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and nine months ended September 30, 2024 and 2023 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of November 7, 2024 should be read in conjunction with the Septemb
November 7, 2024	EX-99.4	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2024. 2. No misrepresentations: Based
November 7, 2024	EX-99.1	Profound Medical Announces Third Quarter 2024 Financial Results EXHIBIT 99.1 Profound Medical Announces Third Quarter 2024 Financial Results TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended
November 7, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 7, 2024	EX-99.2	PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) September 30, 2024 $ December 31, 2023 $ Assets Current assets Cash 27,123 26,213 Trade and other receivables (note 3) 7,030 7,288 Inventory (note 4) 6,435 6,989 Prepa
November 7, 2024	EX-99.5	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2024. 2. No misrepresentations: Based on
November 4, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 4, 2024	EX-99.1	Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 – TULSA to stand above all other covered prostate disease treatment modalities at Urology Level EXHIBIT 99.1 Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025 – TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective January 1, 2025 – TORONTO, Nov. 04, 2024 (GLOBE NEWSWIRE
October 17, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
October 17, 2024	EX-99.1	Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release Third Quarter 2024 Financial Results on November 7 – Conference Call to Follow TORONTO, Oct. 17, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
October 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
October 16, 2024	EX-99.1	Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer – Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to mak EXHIBIT 99.1 Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer – Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final preparations for the permanent CPT® Category 1 codes for TULSA going into effect at the beginning of 2025 – TORONTO, Oct. 16, 202
September 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
September 16, 2024	EX-99.1	Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA - Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemen EXHIBIT 99.1 Profound Medical’s PRO-Talk Live! Event Features the Present and Future of TULSA - Educational event for physicians by physicians; participants heard from an esteemed panel of experts, innovators, and guest speakers - - Global medtech leaders, Siemens Healthineers and Cook Medical, shared their common vision with Profound of creating a total diagnostic and interventional MR solution f
September 12, 2024	S-8	As filed with the Securities and Exchange Commission on September 12, 2024 As filed with the Securities and Exchange Commission on September 12, 2024 Registration No.
September 12, 2024	EX-FILING FEES	Filing Fee Table. EX-FILING FEES Calculation of Filing Fee Tables Form S-8 (Form Type) Profound Medical Corp.
September 4, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
September 4, 2024	EX-99.1	Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference EXHIBIT 99.1 Profound Medical to Participate in Lake Street’s Best Ideas Growth Conference TORONTO, Sept. 04, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participa
August 8, 2024	EX-99.3	PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and six months ended June 30, 2024 and 2023 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of August 8, 2024 should be read in conjunction with the March 31, 2024 unaud
August 8, 2024	EX-99.4	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended June 30, 2024. 2. No misrepresentations: Based on m
August 8, 2024	EX-99.5	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended June 30, 2024. 2. No misrepresentations: Based on my kn
August 8, 2024	EX-99.1	Profound Medical Announces Second Quarter 2024 Financial Results EXHIBIT 99.1 Profound Medical Announces Second Quarter 2024 Financial Results TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ende
August 8, 2024	EX-99.2	PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) June 30, 2024 $ December 31, 2023 $ Assets Current assets Cash 34,079 26,213 Trade and other receivables (note 3) 7,162 7,288 Inventory (note 4) 6,732 6,989 Prepaid expense
August 8, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-390 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princi
August 5, 2024	SC 13G/A	PROF / Profound Medical Corp. / Bdc Capital Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Profound Medical Corp. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74319B502 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
July 18, 2024	EX-99.1	Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow TORONTO, July 18, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its s
July 18, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principa
July 11, 2024	F-10/A	As filed with the Securities and Exchange Commission on July 10, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 10, 2024.
June 14, 2024	EX-7.1	Form of Indenture Exhibit 7.1 PROFOUND MEDICAL CORP. as Issuer, [] as U.S. Trustee and [] as Canadian Trustee Indenture Dated as of [] Table of Contents Page Article One DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01. Definitions 1 Section 1.02. Compliance Certificates and Opinions 12 Section 1.03. Form of Documents Delivered to Trustees 12 Section 1.04. Acts of Holders 13 Section 1.05. Noti
June 14, 2024	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Profound Medical Corp. (“Profound” or the “Company”) Unit 6, 2400 Skymark Avenue Mississauga, Ontario L4W 5K5 2. Date of Material Change January 16, 2024 3. News Release A press release relating to the material change was disseminated via Globe Newswire on January 16, 2024 and was subsequently filed on SEDAR+. 4. Summ
June 14, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of p
June 14, 2024	F-X	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X Appointment of Agent For Service of Process And Undertaking UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X Appointment of Agent For Service of Process And Undertaking A. Name of issuer or person filing (the “Filer”): Profound Medical Corp. B. (1) This is (check one): x  an original filing for the Filer ¨   an amended filing for the Filer       (2) Check the following box if you are filing the Form F-X in paper in accordanc
June 14, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables FORM F-10 (Form Type) PROFOUND MEDICAL CORP.
June 14, 2024	F-10	As filed with the Securities and Exchange Commission on June 14, 2024. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 14, 2024.
June 3, 2024	EX-99.1	PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 5, 2024 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 5, 2024 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual general meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) in the capita
June 3, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
May 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 16, 2024	EX-99.1	Profound Medical Annual General Meeting of Shareholders Voting Results EXHIBIT 99.1 Profound Medical Annual General Meeting of Shareholders Voting Results TORONTO, May 15, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual General Meeting of Shareholders that was held today (the “Meeting”). A total of 15,336,388 common shares, representing 62.78% of the common
May 14, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 14, 2024	EX-99.1	Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan – Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 p EXHIBIT 99.1 Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan – Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training images – – Validated in standalone and multi-reader, multi-case clinical studies conducted by wor
May 9, 2024	EX-99.4	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended March 31, 2024. 2. No misrepresentations: Based on
May 9, 2024	EX-99.1	Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance EXHIBIT 99.1 Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance TORONTO, May 09, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported fina
May 9, 2024	EX-99.2	PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) March 31, 2024 $ December 31, 2023 $ Assets Current assets Cash 41,180 26,213 Trade and other receivables (note 3) 6,510 7,288 Inventory (note 4) 6,976 6,989 Prepaid expen
May 9, 2024	EX-99.5	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended March 31, 2024. 2. No misrepresentations: Based on my k
May 9, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 9, 2024	EX-99.3	PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2024 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three months ended March 31, 2024 and 2023 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of May 9, 2024 should be read in conjunction with the March 31, 2024 unaudited inte
May 6, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 6, 2024	EX-99.1	Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum — So far this year alone, 25 TULSA-related scientific research presen EXHIBIT 99.1 Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum — So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists
April 22, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
April 22, 2024	EX-99.1	Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow TORONTO, April 22, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its firs
April 9, 2024	EX-99.1	Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference EXHIBIT 99.1 Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference TORONTO, April 09, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that managemen
April 9, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
March 13, 2024	SC 13G/A	PROF / Profound Medical Corp. / DASEKE DON R - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Profound Medical Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 74319B502 (CUSIP Number) March 7, 2024
March 7, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
March 7, 2024	EX-97	Profound Medical Corp.’s Clawback Policy Exhibit 97 PROFOUND MEDICAL CORP. CLAWBACK POLICY I.Introduction The Board of Directors (the “Board”) of Profound Medical Corp. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefo
March 7, 2024	40-F	United States Securities and Exchange Commission Washington, D.C. 20549 Form 40-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 40-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission File Number 001-39032 Profound Medical Corp. (Exact name of Registrant as specified
March 7, 2024	EX-99.1	Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results TORONTO, March 07, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the four
March 7, 2024	EX-99.3	Consolidated Financial Statements of the Company for its fiscal year ended December 31, 2023 Exhibit 99.3 PROFOUND MEDICAL CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 PRESENTED IN US DOLLARS (000s) Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Profound Medical Corp. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Profound Medical Corp. and
March 7, 2024	EX-99.2	The management’s discussion and analysis of financial condition and results of operations of the Registrant for the financial years ended December 31, 2023 and December 2022 (incorporated by reference to Exhibit 99.2 to the Annual Report Form 40-F, filed on March 7, 2024). Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS DECEMBER 31, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the years ended December 31, 2023 and 2022 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of March 7, 2024 should be read in conjunction with the December 31, 2023 audited co
March 7, 2024	EX-99.6	Consent of Independent Registered Public Accounting Firm Exhibit 99.6 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in this Annual Report on Form 40-F for the year ended December 31, 2023 of Profound Medical Corp. of our report dated March 7, 2024, relating to the consolidated financial statements which appears in Exhibit 99.3 incorporated by reference in this Annual Report on Form 40-F. We
March 7, 2024	EX-99.1	the annual information form of the Corporation for the year ended December 31, 2023 dated March 7, 2024 (the “ Table of Contents Exhibit 99.1 PROFOUND MEDICAL CORP. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2023 March 7, 2024 Table of Contents TABLE OF CONTENTS Page SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS 1 MARKET AND INDUSTRY DATA 2 TRADEMARKS AND TRADE NAMES 2 GLOSSARY 2 ITEM 1. CORPORATE STRUCTURE 5 ITEM 2. GENERAL DEVELOPMENT OF THE BUSINESS 7 ITEM 3. NARRATIVE DESCRIPTION OF TH
March 7, 2024	EX-99.5	Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of United States Code, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 99.5 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 40-F of Profound Medical Corp. (the “Company”) for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company cert
March 7, 2024	EX-99.4	Certifications required by Rule 13a-14(a) or Rule 15d-14(a), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 99.4 CERTIFICATION I, Arun Menawat, certify that: 1. I have reviewed this annual report on Form 40-F of Profound Medical Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
March 4, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
March 4, 2024	EX-99.1	Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference EXHIBIT 99.1 Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference TORONTO, March 04, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will pa
February 27, 2024	EX-99.1	Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure EXHIBIT 99.1 Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tis
February 27, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
February 15, 2024	EX-99.1	Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will a
February 15, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
February 13, 2024	SC 13G/A	PROF / Profound Medical Corp. / GAGNON SECURITIES LLC - SC 13G/A Passive Investment SC 13G/A 1 profound13ga6.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Profound Medical Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 74319B502 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
January 16, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
January 16, 2024	EX-99.1	Profound Medical Announces Non-Brokered Private Placement EXHIBIT 99.1 Profound Medical Announces Non-Brokered Private Placement TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce that the Company has entered into subscription agreements, dated as of January 16, 2024, with certain existing Canadian institutional investors, in connection with a non-brokered private p
January 11, 2024	SC 13G	PROF / Profound Medical Corp. / DASEKE DON R - THE SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Profound Medical Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 74319B502 (CUSIP Number) January 10, 202
January 11, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13g14015prof12212023.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statements on Schedule 13G with respect to the Common Shares, no par value, of Profound Medical Corp., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with
January 3, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
January 3, 2024	EX-99.1	Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues EXHIBIT 99.1 Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaud
January 2, 2024	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
January 2, 2024	EX-99.1	FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Profound Medical Corp. (“Profound” or the “Company”) Unit 6, 2400 Skymark Avenue Mississauga, Ontario L4W 5K5 2. Date of Material Change December 27, 2023 3. News Release Press releases relating to the material change were disseminated via Globe Newswire on December 27, 2023 and were subsequently filed on SEDAR+. 4. S
December 28, 2023	EX-99.1	Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares Exhibit 99.1 Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares TORONTO, ON (December 27, 2023) - Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 2,666,667 common shares (the “Common Shares”) at a price to the public of US$7.50 per C
December 28, 2023	EX-99.1	2,666,667 COMMON SHARES PROFOUND MEDICAL CORP. UNDERWRITING AGREEMENT Exhibit 99.1 2,666,667 COMMON SHARES PROFOUND MEDICAL CORP. UNDERWRITING AGREEMENT December 27, 2023 Titan Partners Group LLC, a division of American Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Titan Partners Group LLC, a division of American Capital Partners, LLC 4 World Trade Center, 29th Floor New York, NY 10007 Ladies and Gent
December 28, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of
December 28, 2023	SUPPL	PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED MARCH 23, 2022 TABLE OF CONTENTS FILED PURSUANT TO GENERAL INSTRUCTION II.L. OF FORM F-10 FILE NO. 333-263248 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated March 23, 2022 to which it relates, as amended or supplemented, and each document incorporate
December 28, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of
December 27, 2023	EX-99.1	Profound Medical Announces Proposed Public Offering of Common Shares EXHIBIT 99.1 Profound Medical Announces Proposed Public Offering of Common Shares TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the “Offering”). The Company inten
December 27, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of
December 27, 2023	EX-99.1	Profound Medical Announces Proposed Public Offering of Common Shares Exhibit 99.1 Profound Medical Announces Proposed Public Offering of Common Shares TORONTO, ON (December 27, 2023) - Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the “Offering”). The Company intends to f
December 27, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
December 27, 2023	SUPPL	PRELIMINARY PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED MARCH 23, 2022 TABLE OF CONTENTS FILED PURSUANT TO GENERAL INSTRUCTION II.L. OF FORM F-10 FILE NO. 333-263248 SUBJECT TO COMPLETION, DATED DECEMBER 27, 2023 The information contained in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commissi
November 8, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 8, 2023	EX-99.1	Profound Medical to Participate in the Stifel 2023 Healthcare Conference EXHIBIT 99.1 Profound Medical to Participate in the Stifel 2023 Healthcare Conference TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an upda
November 3, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 3, 2023	EX-99.1	Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting EXHIBIT 99.1 Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting TORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, pursuant to the 2
November 2, 2023	EX-99.4	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2023. 2. No misrepresentations: Based
November 2, 2023	EX-99.1	Profound Medical Announces Third Quarter 2023 Financial Results EXHIBIT 99.1 Profound Medical Announces Third Quarter 2023 Financial Results TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended
November 2, 2023	EX-99.2	PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s) Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) September 30, 2023 $ December 31, 2022 $ Assets Current assets Cash 33,625 46,517 Trade and other receivables (note 3) 6,619 6,344 Inventory (note 4) 7,425 7,941 Prepa
November 2, 2023	EX-99.3	PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s) Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and nine months ended September 30, 2023 and 2022 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of November 2, 2023 should be read in conjunction with the Septemb
November 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 2, 2023	EX-99.5	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended September 30, 2023. 2. No misrepresentations: Based on
October 19, 2023	EX-99.1	Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
October 19, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
October 10, 2023	EX-99.1	Profound Medical 2023 Virtual Analyst & Investor Day Agenda EXHIBIT 99.1 Profound Medical 2023 Virtual Analyst & Investor Day Agenda TORONTO, Oct. 10, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today additional details regarding its Analyst & Invest
October 10, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
September 25, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
September 25, 2023	EX-99.1	Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsule EXHIBIT 99.1 Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost The first of the TULSA AI modules, Thermal Boost enables predictable, customized ablation at the prostate capsule TORONTO, Sept. 25, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets cust
September 21, 2023	EX-99.1	Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13 EXHIBIT 99.1 Save the Date: Profound Medical to Host Virtual Analyst & Investor Day on October 13 TORONTO, Sept. 21, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host an Analyst & Investor Day eve
September 21, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
September 19, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
September 19, 2023	EX-99.1	Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference EXHIBIT 99.1 Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present
September 7, 2023	EX-99.1	Profound Medical Announces At-the-Market Offering of up to US$30,000,000 EXHIBIT 99.1 Profound Medical Announces At-the-Market Offering of up to US$30,000,000 TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) announces that it has established an at-the-market equity program (the “ATM Program”) that allows the Company, through certain securities dealers acting as agents (together, the “Agents“), to i
September 7, 2023	EX-99.4	Osler, Hoskin & Harcourt Exhibit 99.4 Osler, Hoskin & Harcourt llp Box 50, 1 First Canadian Place Toronto, Ontario, Canada M5X 1B8 416.362.2111 main 416.862.6666 facsimile Toronto Montréal Calgary Ottawa Vancouver New York September 6, 2023 Profound Medical Corp. 2400 Skymark Avenue, Unit #6 Mississauga, Ontario L4W 5K5 Dear Sirs/Mesdames: Profound Medical Corp. (the “Issuer”) We refer you to the prospectus supplement dat
September 7, 2023	EX-99.3	Boston Los Angeles New York San Diego San Francisco toronto Washington MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. Exhibit 99.3 200 Bay Street, South Tower Suite 2800 Toronto, ON 647 499 2828 mintz.com September 6, 2023 Profound Medical Corp. 2400 Skymark Avenue, Unit #6 Mississauga, Ontario L4W 5K5 Dear Sirs/Mesdames: Re: Profound Medical Corp. - Prospectus Supplement dated September 6, 2023 to the Short Form Base Shelf Prospectus dated March 23, 2022 (the “Prospectus Supplement”) We hereby consent to the ref
September 7, 2023	EX-99.2	PROFOUND MEDICAL CORP. Up to US$30,000,000 of Common Shares Equity Distribution Agreement Exhibit 99.2 PROFOUND MEDICAL CORP. Up to US$30,000,000 of Common Shares Equity Distribution Agreement September 6, 2023 Stifel Nicolaus Canada Inc. 161 Bay Street, Suite 3800 Toronto, ON M5J 2S1 Stifel, Nicolaus & Company, Incorporated One South Street 15th Floor Baltimore, Maryland 21202 Ladies and Gentlemen: Profound Medical Corp., a corporation organized under the laws of the Province of Ontar
September 7, 2023	EX-99.1	Profound Medical Announces At-the-Market Offering of up to US$30,000,000 Exhibit 99.1 Profound Medical Announces At-the-Market Offering of up to US$30,000,000 TORONTO, ON (September 6, 2023) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) announces that it has established an at-the-market equity program (the “ATM Program”) that allows the Company, through certain securities dealers acting as agents (together, the “Agents“), to issue and
September 7, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of
September 7, 2023	SUPPL	PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED MARCH 23, 2022 TABLE OF CONTENTS FILED PURSUANT TO GENERAL INSTRUCTION II.L. OF FORM F-10 FILE NO. 333-263248 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated March 23, 2022 to which it relates, as amended or supplemented, and each document incorporated
September 7, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
August 9, 2023	EX-99.5	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended June 30, 2023. 2. No misrepresentations: Based on my kn
August 9, 2023	EX-99.4	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended June 30, 2023. 2. No misrepresentations: Based on m
August 9, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-390 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pr
August 9, 2023	EX-99.3	PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2023 PRESENTED IN US DOLLARS (000s) Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS JUNE 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and six months ended June 30, 2023 and 2022 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of August 9, 2023 should be read in conjunction with the June 30, 2023 unaudi
August 9, 2023	EX-99.1	Profound Medical Announces Second Quarter 2023 Financial Results EXHIBIT 99.1 Profound Medical Announces Second Quarter 2023 Financial Results TORONTO, Aug. 09, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ende
August 9, 2023	EX-99.2	PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2023 PRESENTED IN US DOLLARS (000s) Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) June 30, 2023 $ December 31, 2022 $ Assets Current assets Cash 39,275 46,517 Trade and other receivables (note 3) 6,586 6,344 Inventory (note 4) 8,056 7,941 Prepaid expense
August 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-390 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princi
August 2, 2023	EX-99.1	Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release Second Quarter 2023 Financial Results on August 9 – Conference Call to Follow TORONTO, Aug. 02, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its s
June 2, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principa
June 2, 2023	EX-99.1	Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases EXHIBIT 99.1 Profound Medical Announces New CPT® Category 1 Codes from the AMA for TULSA to Treat Prostate Diseases TORONTO, June 02, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that,
May 30, 2023	EX-99.1	Profound Medical Announces Upcoming Investor Events EXHIBIT 99.1 Profound Medical Announces Upcoming Investor Events TORONTO, May 30, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announces the following investor events in June: PRO-Talk Episode 5, “Unlo
May 30, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 18, 2023	EX-99.1	Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference EXHIBIT 99.1 Profound Medical to Participate in A.G.P.’s Virtual Healthcare Conference TORONTO, May 18, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in A.G.P.
May 18, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 17, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 17, 2023	EX-99.1	Profound Medical Annual and Special Meeting of Shareholders Voting Results EXHIBIT 99.1 Profound Medical Annual and Special Meeting of Shareholders Voting Results TORONTO, May 17, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). A total of 13,437,920 common shares, representing 63.64% of th
May 10, 2023	EX-99.5	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended March 31, 2023. 2. No misrepresentations: Based on my k
May 10, 2023	EX-99.2	PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2023 PRESENTED IN US DOLLARS (000s) Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) March 31, 2023 $ December 31, 2022 $ Assets Current assets Cash 42,984 46,517 Trade and other receivables (note 3) 6,995 6,344 Inventory (note 4) 8,125 7,941 Prepaid expen
May 10, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
May 10, 2023	EX-99.1	Profound Medical Announces First Quarter 2023 Financial Results EXHIBIT 99.1 Profound Medical Announces First Quarter 2023 Financial Results TORONTO, May 10, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended M
May 10, 2023	EX-99.3	PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2023 PRESENTED IN US DOLLARS (000s) Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS MARCH 31, 2023 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three months ended March 31, 2023 and 2022 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of May 10, 2023 should be read in conjunction with the March 31, 2023 unaudited int
May 10, 2023	EX-99.4	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Profound Medical Corp. (the “issuer”) for the interim period ended March 31, 2023. 2. No misrepresentations: Based on
May 1, 2023	EX-99.1	CREDIT AGREEMENT PROFOUND MEDICAL INC. as Borrower PROFOUND MEDICAL CORP. 2753079 ONTARIO INC. PROFOUND MEDICAL (U.S.) INC. and PROFOUND MEDICAL GMBH as Guarantors CANADIAN IMPERIAL BANK OF COMMERCE as Lender dated as of November 3, 2022 GOODMANS LLP Exhibit 99.1 EXECUTION COPY INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. CREDIT AGREEMENT between PROFOUND MEDICAL INC. as Borrower AND PROFOUND MEDICAL CORP. 2753079 ONTARIO INC. PROFOUND MEDICAL (U.S.) INC. and PROFOUND MEDICAL GMBH as
May 1, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of principal
May 1, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
May 1, 2023	EX-99.1	TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting – Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its potential as a mainstream, whol EXHIBIT 99.1 TULSA Procedure Featured in the Scientific Program at the American Urological Association 2023 Annual Meeting – Presentations reinforce the safety, efficacy and durability of the TULSA procedure, further supporting its potential as a mainstream, whole gland or focal treatment for prostate disease – – FARP study provides Level 1 evidence that focal therapy with TULSA has a lower compli
April 25, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of the registrant’s name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri
April 25, 2023	EX-99.1	PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 17, 2023 MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 6, 2023 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 17, 2023 AND MANAGEMENT INFORMATION CIRCULAR DATED AS OF APRIL 6, 2023 PROFOUND MEDICAL CORP. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN THAT an annual and special meeting (the “Meeting”) of the holders (the “Shareholders”) of common shares (“Common Shares”) i
April 25, 2023	EX-99.2	Form of Proxy Exhibit 99.2
April 19, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
April 19, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
April 19, 2023	EX-99.1	Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow TORONTO, April 19, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fir
April 19, 2023	EX-99.1	Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference EXHIBIT 99.1 Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference TORONTO, April 19, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that manage
March 7, 2023	EX-99.1	Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA EX-99.1 2 exh991.htm PRESS RELEASE EXHIBIT 99.1 Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results Company confirms Current Procedural Terminology (“CPT®”) Category 1 application for TULSA TORONTO, March 07, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and mar
March 7, 2023	40-F	United States Securities and Exchange Commission Washington, D.C. 20549 Form 40-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 40-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission File Number 001-39032 Profound Medical Corp. (Exact name of Registrant as specified
March 7, 2023	EX-99.3	Consolidated Financial Statements of the Company for its fiscal year ended December 31, 2022 Exhibit 99.3 PROFOUND MEDICAL CORP. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021 PRESENTED IN US DOLLARS (000s) Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Profound Medical Corp. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Profound Medical Corp. and
March 7, 2023	EX-99.6	Consent of Independent Registered Public Accounting Firm Exhibit 99.6 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Annual Report on Form 40-F for the year ended December 31, 2022, and in the Registration Statements on Form F-10 (333-263248) and S-8 (333-238528 and 333-234574) of our report dated March 7, 2023, relating to the consolidated financial statements, which appears in this F
March 7, 2023	EX-99.4	Certifications required by Rule 13a-14(a) or Rule 15d-14(a), pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Exhibit 99.4 CERTIFICATION I, Arun Menawat, certify that: 1. I have reviewed this annual report on Form 40-F of Profound Medical Corp.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
March 7, 2023	EX-99.1	the annual information form of the Corporation for the year ended December 31, 2022 dated March 7, 2023, as filed on SEDAR+ and also contained in Exhibit 99.1 of the Form 40-F of the Corporation filed with the SEC on March 7, 2023 (the “ Table of Contents Exhibit 99.1 PROFOUND MEDICAL CORP. ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2022 March 7, 2023 Table of Contents TABLE OF CONTENTS Page SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS 1 MARKET AND INDUSTRY DATA 2 TRADEMARKS AND TRADE NAMES 2 GLOSSARY 2 ITEM 1. CORPORATE STRUCTURE 6 ITEM 2. GENERAL DEVELOPMENT OF THE BUSINESS 8 ITEM 3. NARRATIVE DESCRIPTION OF TH
March 7, 2023	EX-99.2	the management’s discussion and analysis of financial condition and results of operations of the Corporation for the years ended December 31, 2022 and 2021, as filed on SEDAR+ and also contained in Exhibit 99.2 of the Form 40-F of the Corporation filed with the SEC on March 7, 2023 (the “ Exhibit 99.2 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS DECEMBER 31, 2022 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the years ended December 31, 2022 and 2021 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of March 7, 2023 should be read in conjunction with the December 31, 2022 audited co
March 7, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
March 7, 2023	EX-99.5	Certifications required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of United States Code, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Exhibit 99.5 Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Annual Report on Form 40-F of Profound Medical Corp. (the “Company”) for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company cert
March 1, 2023	EX-99.1	Profound Medical to Present at the 43rd Annual Cowen Health Care Conference EXHIBIT 99.1 Profound Medical to Present at the 43rd Annual Cowen Health Care Conference TORONTO, March 01, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Arun
March 1, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-3903 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princip
February 14, 2023	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
February 14, 2023	EX-99.1	Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will a
February 13, 2023	SC 13G/A	PROF / Profound Medical Corp. / GAGNON SECURITIES LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Profound Medical Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 74319B502 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th
February 10, 2023	SC 13G/A	PROF / Profound Medical Corp. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 6, 2023	SC 13G/A	PROF / Profound Medical Corp. / GAGNON SECURITIES LLC - SC 13G/A Passive Investment SC 13G/A 1 profound13ga5.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Profound Medical Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 74319B502 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des
November 8, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 8, 2022	EX-99.1	Profound Medical to Present at the 2022 Jefferies London Healthcare Conference EXHIBIT 99.1 Profound Medical to Present at the 2022 Jefferies London Healthcare Conference TORONTO, Nov. 08, 2022 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (?Profound? or the ?Company?), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that its CEO and Chairman, Aru
November 3, 2022	EX-99.2	PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2022 PRESENTED IN US DOLLARS (000s) Exhibit 99.2 PROFOUND MEDICAL CORP. INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS SEPTEMBER 30, 2022 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Interim Condensed Consolidated Balance Sheets In USD (000s) (Unaudited) September 30, 2022 $ December 31, 2021 $ Assets Current assets Cash 46,208 67,152 Trade and other receivables (note 3) 3,458 1,412 Inventory (note 4) 7,440 7,413 Prepa
November 3, 2022	EX-99.3	PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2022 PRESENTED IN US DOLLARS (000s) EX-99.3 4 exh993.htm EXHIBIT 99.3 Exhibit 99.3 PROFOUND MEDICAL CORP. MANAGEMENT’S DISCUSSION AND ANALYSIS SEPTEMBER 30, 2022 PRESENTED IN US DOLLARS (000s) Profound Medical Corp. Management’s Discussion and Analysis For the three and nine months ended September 30, 2022 and 2021 In USD$ (000s) The following Management’s Discussion and Analysis (“MD&A”) prepared as of November 3, 2022, should be r
November 3, 2022	EX-99.5	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.5 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Rashed Dewan, the Chief Financial Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Profound Medical Corp. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: Based
November 3, 2022	EX-99.4	FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Arun Menawat, the Chief Executive Officer of Profound Medical Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Profound Medical Corp. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations: Based
November 3, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of prin
November 3, 2022	EX-99.1	Profound Medical Announces Third Quarter 2022 Financial Results Exhibit 99.1 Profound Medical Announces Third Quarter 2022 Financial Results TORONTO, Nov. 03, 2022 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (?Profound? or the ?Company?), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the third quarter ended
October 13, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2022 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of princ
October 13, 2022	EX-99.1	Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow EXHIBIT 99.1 Profound Medical to Release Third Quarter 2022 Financial Results on November 3 ? Conference Call to Follow TORONTO, Oct. 13, 2022 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (?Profound? or the ?Company?), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its
October 11, 2022	SC 13G/A	PROF / Profound Medical Corp. / GAGNON SECURITIES LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Profound Medical Corp. (Name of Issuer) Common Shares (Title of Class of Securities) 74319B502 (CUSIP Number) October 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S
September 26, 2022	EX-99.1	Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer EXHIBIT 99.1 Four Year Follow-Up Data from Profound Medical?s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO? of Men with Localized Prostate Cancer TORONTO, Sept. 26, 2022 (GLOBE NEWSWIRE) - Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (?Profound? or the ?Company?), a commercial-stage medical device company that develops and markets custo
September 26, 2022	6-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File Number: 001-39032 PROFOUND MEDICAL CORP. (Translation of registrant's name into English) 2400 Skymark Avenue, Unit 6, Mississauga, Ontario L4W 5K5 (Address of pri

PROF / Profound Medical Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)

Other Listings